home / stock / rare / rare news

RARE News and Press, Ultragenyx Pharmaceutical Inc. From 02/23/26

Stock Information
Company Name: Ultragenyx Pharmaceutical Inc.
Stock Symbol: RARE
Market: NASDAQ
Website: ultragenyx.com
Menu
RARE RARE Quote RARE Short RARE News RARE Articles RARE Message Board
Get RARE Alerts

News, Short Squeeze, Breakout and More Instantly...
RARE - Ultragenyx to Participate at Investor Conferences in March

NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming invest...
RARE - Rare disease pharmas could benefit from FDA guidance to accelerate development

2026-02-23 14:34:32 ET More on CRISPR Therapeutics, Intellia Therapeutics Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Crispr: Emphasis Shifts...

RARE - Ultragenyx granted FDA priority review for rare metabolic disorder gene therapy

2026-02-23 10:59:56 ET More on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline Ultragenyx Pharmaceutical Inc. (RARE) Presents at ...

RARE - Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or t...
RARE - Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript

2026-02-13 18:47:46 ET Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST... Read the full article on Seeking Alpha For further details see: Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript

RARE - Ultragenyx falls as guidance trails consensus amid job cuts

2026-02-13 14:42:09 ET More on Ultragenyx Pharmaceutical Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ultragenyx: Wh...

RARE - Ultragenyx (RARE) Q4 2025 Earnings Call Transcript

2026-02-12 18:38:25 ET Image source: The Motley Fool. Thursday, Feb. 12, 2026 at 5 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
RARE - Ultragenyx Pharmaceutical GAAP EPS of -$1.29 misses by $0.16, revenue of $207M beats by $5.14M

2026-02-12 16:06:46 ET More on Ultragenyx Pharmaceutical Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ultragenyx: Wh...

RARE - Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

2025 total revenue of $673 million, Crysvita ® revenue of $481 million and Dojolvi ® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce and focus...

RARE - Expected US Company Earnings on Thursday, February 12th, 2026

Baxter International Inc. (BAX) is expected to report $0.53 for Q4 2025 Nova Ltd. (NVMI) is expected to report $1.94 for Q4 2025 West Pharmaceutical Services Inc. (WST) is expected to report $1.83 for Q4 2025 Universal Logistics Holdings Inc. (ULH) is expected to report $-0.05 for Q4 ...
Previous 10 Next 10